Search

Displaying results 9271 - 9280 of 10000 in total

Drug
Telcagepant
go.drugbank.com/drugs/DB12228
Investigational
It is an antagonist of the receptor for calcitonin gene-related peptide (CGRP), a primary neuropeptide involved in the pathophysiology of migraine.
Categories: Heterocyclic Compounds, 1-Ring
Drug
Temefos
go.drugbank.com/drugs/DB12231
Investigational
Diphos has been used in trials studying the treatment of Plasmodium Falciparum Malaria.
Categories: Compounds used in a research, industrial, or household setting
Drug
AZD-7762
go.drugbank.com/drugs/DB12242
Investigational
AZD7762 has been investigated for the treatment of Cancer, Solid Tumors, and Advanced Solid Malignancies.
Categories: Heterocyclic Compounds, 1-Ring
Drug
Moxaverine
go.drugbank.com/drugs/DB12251
Investigational
Moxaverine has been investigated for the treatment of Retina, Ocular Physiology, and Regional Blood Flow.
Categories: Heterocyclic Compounds, 2-Ring
Drug
Platinum
go.drugbank.com/drugs/DB12257
Investigational
Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer, Gastric Large Cell Neuroendocrine Carcinoma, Colorectal Large Cell Neuroendocrine Carcinoma, and Pancreatic Large Cell Neuroendocr...
Categories: Compounds used in a research, industrial, or household setting
Drug
Losmapimod
go.drugbank.com/drugs/DB12270
Investigational
Losmapimod has been investigated for the prevention of Chronic Obstructive Pulmonary Disease.
Categories: Heterocyclic Compounds, 1-Ring
Drug
ORE-1001
go.drugbank.com/drugs/DB12271
Investigational
ORE1001 has been used in trials studying the treatment of Mild to Moderate Ulcerative Colitis. It is an ACE2 inhibitor.
Categories: Heterocyclic Compounds, 1-Ring
Drug
Seviteronel
go.drugbank.com/drugs/DB12275
Investigational
Seviteronel has been used in trials studying the treatment of CRPC, Prostate Cancer, and Castration-resistant Prostate Cancer.
Categories: Heterocyclic Compounds, 1-Ring, Cytochrome P-450 Enzyme Inhibitors
Drug
Luspatercept
go.drugbank.com/drugs/DB12281
ApprovedInvestigational
Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1. … [A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients with beta thalassemia who require regular blood
Products: REBLOZYL®
Drug
LY-2608204
go.drugbank.com/drugs/DB12284
Investigational
LY2608204 has been used in trials studying the treatment of Diabetes Mellitus, Type 2.
Categories: Heterocyclic Compounds, 1-Ring